Iliad Biotechnologies Announces $42.8M Financing Round To Advance Bpze1 Pertussis Vaccine
09/06/22, 2:07 PM
Location
westonMoney raised
$42.8 million
Industry
biotechnology
ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine, today announced the closing of a $42.8 million Class D round of financing. These funds will enable the company to conduct a Phase 2b Human Challenge study to determine if vaccination with BPZE1 prevents colonization from wild-type Bordetella pertussis infection.
Company Info
Location
4581 weston road
weston, florida, united states
Additional Info
ILiAD Biotechnologies is utilizing its B-Tech vector platform to develop next generation vaccines to eradicate infectious diseases and improve lives. Its lead candidate, BPZE1, which has completed Phase 2 clinical trials, is the most advanced next generation vaccine for the prevention of whooping cough, a serious illness caused by Bordetella pertussis.